作为减少非膜性心房动中风风险的策略,左心房附属物阻塞是非膜性心房动中风风险的策略
Errol Moras1, Kruti Gandhi1, Shreyas Yakkali2
1From the Department of Internal Medicine, Icahn School of Medicine at Mount Sinai, New York, NY.
Cardiology in review
|July 30, 2024
概括
左心房尾阻塞 (LAAO) 为非膜心房动 (AF) 患者提供了一种中风预防替代方案. 这种方法准了血栓的主要来源,减少了中风风险,没有长期的抗凝风险.
科学领域:
- 心脏病学 心脏病学
- 医疗器械 医疗器械
- 干预心脏病学 干预心脏病学
背景情况:
- 非膜性心房动 (AF) 是一种普遍的疾病,与高风险的缺血性中风和全身栓塞有关.
- 左心房附属体 (LAA) 是AF患者血栓形成的主要来源,导致栓塞事件.
- 目前的中风预防策略,如口服抗凝剂,携带重大出血的风险,并要求患者严格遵守.
研究的目的:
- 为提供关于左心房附属物阻塞 (LAAO) 作为非膜性AF中风预防策略的综合性审查.
- 讨论LAA的解剖学及其在血栓形成中的作用.
- 总结各种LAAO技术,设备和支持其有效性的临床证据.
主要方法:
- 对LAA解剖学,血栓形成和LAAO技术的现有文献的审查.
- 随机对照试验和临床研究的分析,评估LAAO对中风风险的降低.
- 与抗凝治疗相比,关于LAAO的安全性和有效性的证据综合.
主要成果:
- 这种LAA涉及90%以上的AF相关血栓瘤.
- 包括穿皮和外科手术在内的LAAO技术在降低中风风险方面表现出有希望的结果.
- 临床试验表明,LAAO可以作为选择AF患者中风预防的长期抗凝药的有效替代品.
结论:
- LAAO是一种新兴的有效策略,用于预防非膜AF患者的中风.
- 这种干预措施解决了栓塞事件的主要来源,为抗凝治疗提供了替代方案.
- 进一步的证据支持LAAO作为一种有价值的选择,用于管理AF日益增长的人群中风风险.
相关概念视频
01:27Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
01:28Antihypertensive Drugs: Types of β-Blockers
β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and vasodilation. This widens airways and...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:22Heart Failure Drugs: β-Blockers
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
01:26Imbalances in Cardiac Output
The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send blood...
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send blood...
01:30Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...